Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception.

Leistungen

Communication and dissemination plan: Details on the dissemination strategy and action plan including analysis of stakeholder groups, identification of key events and activities

Communication and dissemination plan: Details on the dissemination strategyand action plan including analysis of stakeholder groups, identification of keyevents and activities

Project Quality Plan (PQP): rules for meetings management, documents naming and storage, deliverables preparation and quality review

Project Quality Plan (PQP): rules for meetings management, documents namingand storage, deliverables preparation and quality review

Study initiation package – RISP

Study initiation package-RISP (before enrolment of the first study participant) including:oRegistration number of the clinical study in a registry meeting WHO Registry criteriaoFinal version of study protocol as approved by the regulator(s) / ethics committee(s)oRegulatory and ethics (if applicable, institutional) approvals required for the enrolment of the first study participant (In case of multicentre clinical studies, submission of approvals for the first clinical site is sufficient.)

Midterm recruitment report – PREVALUNG ETOILE

Midterm recruitment report-PREVALUNG ETOILE: This report is due when 50% of the study population is recruited. The report shall include an overview of the number of recruited participants by clinical sites, any problems in recruitment and, if applicable, a detailed description of implemented and planned measures to compensate for any incurred delays.

Project Management Plan (PMP): organisation, scope of work, Master Plan, Project Action List, risk register

Project Management Plan (PMP): organisation, scope of work, Master Plan,Project Action List, risk register

First meeting of the PAB minutes
Report on the status of posting results in a repository – FLEMENGHO

Report on the status of posting results in a repository-FLEMENGHO. Irrespective of the successful completion of the clinical study, summary results must be posted in the applicable registry/ies (where the study was registered) even if the timing of posting of results falls outside of the grant period. The report is to be scheduled for the time results posting is expected or for the last months of the project, whichever comes earlier.

Midterm recruitment report – SUMMIT

Midterm recruitment report-SUMMIT: This report is due when 50% of the study population is recruited. The report shall include an overview of the number of recruited participants by clinical sites, any problems in recruitment and, if applicable, a detailed description of implemented and planned measures to compensate for any incurred delays.

Management Board charts signed by members
Midterm recruitment report – PREVALUNG

Midterm recruitment report- PREVALUNG: This report is due when 50% of the study population is recruited. The report shall include an overview of the number of recruited participants by clinical sites, any problems in recruitment and, if applicable, a detailed description of implemented and planned measures to compensate for any incurred delays.

Midterm recruitment report – ROBINSCA

Midterm recruitment report-ROBINSCA: This report is due when 50% of the study population is recruited. The report shall include an overview of the number of recruited participants by clinical sites, any problems in recruitment and, if applicable, a detailed description of implemented and planned measures to compensate for any incurred delays.

Study initiation package – SUMMIT

Study initiation package-SUMMIT (before enrolment of the first study participant) including:oRegistration number of the clinical study in a registry meeting WHO Registry criteriaoFinal version of study protocol as approved by the regulator(s) / ethics committee(s)oRegulatory and ethics (if applicable, institutional) approvals required for the enrolment of the first study participant (In case of multicentre clinical studies, submission of approvals for the first clinical site is sufficient.)

Study initiation package – FLEMENGHO

Study initiation package-FLEMENGHO (before enrolment of the first study participant) including:oRegistration number of the clinical study in a registry meeting WHO Registry criteriaoFinal version of study protocol as approved by the regulator(s) / ethics committee(s)oRegulatory and ethics (if applicable, institutional) approvals required for the enrolment of the first study participant (In case of multicentre clinical studies, submission of approvals for the first clinical site is sufficient.)

Study initiation package – PREVALUNG ETOILE

Study initiation package-PREVALUNG ETOILE (before enrolment of the first study participant) including:oRegistration number of the clinical study in a registry meeting WHO Registry criteriaoFinal version of study protocol as approved by the regulator(s) / ethics committee(s)oRegulatory and ethics (if applicable, institutional) approvals required for the enrolment of the first study participant (In case of multicentre clinical studies, submission of approvals for the first clinical site is sufficient.)

Study initiation package – ROBINSCA

•Study initiation package-ROBINSCA (before enrolment of the first study participant) including:oRegistration number of the clinical study in a registry meeting WHO Registry criteriaoFinal version of study protocol as approved by the regulator(s) / ethics committee(s)oRegulatory and ethics (if applicable, institutional) approvals required for the enrolment of the first study participant (In case of multicentre clinical studies, submission of approvals for the first clinical site is sufficient.)

Study initiation package – NCL TLHC

Study initiation package-NCL TLHC (before enrolment of the first study participant) including:oRegistration number of the clinical study in a registry meeting WHO Registry criteriaoFinal version of study protocol as approved by the regulator(s) / ethics committee(s)oRegulatory and ethics (if applicable, institutional) approvals required for the enrolment of the first study participant (In case of multicentre clinical studies, submission of approvals for the first clinical site is sufficient.)

Study initiation package – PREVALUNG

Study initiation package- PREVALUNG (before enrolment of the first study participant) including:oRegistration number of the clinical study in a registry meeting WHO Registry criteriaoFinal version of study protocol as approved by the regulator(s) / ethics committee(s)oRegulatory and ethics (if applicable, institutional) approvals required for the enrolment of the first study participant (In case of multicentre clinical studies, submission of approvals for the first clinical site is sufficient.)

Midterm recruitment report – FLEMENGHO

Midterm recruitment report-FLEMENGHO: This report is due when 50% of the study population is recruited. The report shall include an overview of the number of recruited participants by clinical sites, any problems in recruitment and, if applicable, a detailed description of implemented and planned measures to compensate for any incurred delays.

Visual identity, website and social media: Project branding, introductory project materials, video, infographics, logo are available, website is published and social media accounts operative

Visual identity, website and social media: Project branding, introductory projectmaterials, video, infographics, logo are available, website is published andsocial media accounts operative

Veröffentlichungen

Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses

Autoren: Shuai Zhang, Liwei Zhao, Mengfei Guo, Peng Liu, Sijing Li, Wei Xie, Ai-Ling Tian, Jonathan G Pol, Hui Chen, Hui Pan, Misha Mao, Yumei Li, Laurence Zitvogel, Yang Jin, Oliver Kepp, Guido Kroemer
Veröffentlicht in: Journal for ImmunoTherapy of Cancer, Ausgabe 11, 2023, ISSN 2051-1426
Herausgeber: BMJ Publishing Group Ltd & Society for Immunotherapy of Cancer
DOI: 10.1136/jitc-2023-006785

1510 Multiomic functional biomarkers for cancer prediction and early detection

Autoren: Marine Fidelle, Deborah Suissa, Roxanne Birebent, et al
Veröffentlicht in: Journal for immunotherapy of cancer, Ausgabe 11, 2023, ISSN 2051-1426
Herausgeber: BMJ Publishing Group Ltd & Society for Immunotherapy of Cancer
DOI: 10.1136/jitc-2023-SITC2023.1510

Bile acids regulate MAdCAM-1 expression to link the gut microbiota to cancer immunosurveillance

Autoren: Marine Fidelle, Ai-Ling Tian, Laurence Zitvogel, Guido Kroemer
Veröffentlicht in: Oncoimmunology, Ausgabe 12, 2023
Herausgeber: Taylor & Francis Group
DOI: 10.1080/2162402X.2023.2224672

Leistungen

Veröffentlichungen

Diese Seite teilen

Herunterladen